Sancuso (granisetron) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

				URGENT		
MEMBER INFORMATION						
LAST NAME:		FIRST NAME:				
PHONE NUMBER:		DATE OF BIRTH:				
STREET ADDRESS:						
CITY:		STATE: ZIP CODE:				
PATIENT INSURANCE ID NUN	/IBER:					
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: F YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):						
PRESCRIBER INFORMATION						
LAST NAME:		FIRST NAME:				
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:				
NPI NUMBER:		DEA NUMBER:				
PHONE NUMBER:		FAX NUMBER:				
STREET ADDRESS:						
CITY:		STATE: ZIP CODE:				
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:				
MEDICATION OR MEDICAL DISPENSING INFORMATION						
MEDICATION NAME:						
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:		QUANTITY:		
□ NEW THERAPY □ RENEWAL IF RENEWAL: DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):						

Continued on next page.



Sancuso (granisetron) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST I	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO			
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR			
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:			
·	·				
2. LIST DIAGNOSES:		ICD-10:			
3 REQUIRED CLINICAL INFORMATION	: PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A			
PRIOR AUTHORIZATION.	TELASE I NOVIDE ALE RELEVANT CENTE	AL INI ORINIATION TO SOLITORITA			
Clinical Information:					
	ancer and is the patient undergoing che	motherapy? □ Yes □ No			
Does the patient have a diagnosis of c	ander and is the patient andergoing the	ouncidpy. E 100 E 110			
Is the medication being prescribed for	the prevention of nausea and vomiting	? □ Yes □ No			
31					
Has the patient previously tried and ha	ad an inadequate response to at least o	ne other anti-emetic? ☐ Yes ☐ No			
	·				
Is the patient receiving highly emetog	enic or moderately emetogenic chemotl	herapy? Yes No			
Are there any other comments, diagno	oses, symptoms, medications tried or fa	iled, and/or any other information the			
physician feels is important to this review?					
Please note: Not all drugs/diagnosis ar	e covered on all plans. This request may	be denied unless all required			
information is received.	, ,	·			
ATTESTATION: I attest the information	n provided is true and accurate to the be	st of my knowledge. I understand that			
	o or its designees may perform a routine	,			
· · · · · · · · · · · · · · · · · · ·	curacy of the information reported on thi	•			
	·				
Prescriber Signature or Electronic I.D.	Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents acco	ompanying this transmission contain confidential	health information that is legally privileged. If			
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents					
of these documents is strictly prohibited. If you	have received this information in error, please no	otify the sender immediately (via return FAX)			

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.